The present invention relates to a process for preparation of 1,3-butylene glycol, the process comprising: (a) stripping off acetaldehyde from a crude mixture comprising acetaldol acetaldehyde and water, at a temperature in a range from 80°C to 90°C, to produce a concentrated acetaldol, (b) hydrogenating the concentrated acetaldol to produce a crude 1,3-butylene glycol, and (c) subjecting the crude 1,3- butylene glycol to azeotropic distillation. The process of the present invention reduces hydrogen consumption in step (b) and further reduces colour and odor causing impurities. The invention also relates to 1,3-butylene glycol having low concentration of colour and odor causing impurities.
C07C 45/78 - SeparationPurificationStabilisationUse of additives
C07C 29/141 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen-containing functional group of C=O containing groups, e.g. —COOH of a —CHO group with hydrogen or hydrogen-containing gases
C07C 29/80 - SeparationPurificationStabilisationUse of additives by physical treatment by distillation
The present invention relates to pharmaceutical compositions comprising compound of Formula IV, along with a solubilizing agent and a process to prepare the same. The said pharmaceutical compositions have enormous applications in cancer therapy. The present invention has come up with a novel and innovative pharmaceutical composition for the compounds of Formula IV that show significant stability as well as the desired bioavailability on drug release.
The present invention relates to pharmaceutical compositions comprising compound of Formula IV, along with a solubilizing agent and a process to prepare the same. The said pharmaceutical compositions have enormous applications in cancer therapy. The present invention has come up with a novel and innovative pharmaceutical composition for the compounds of Formula IV that show significant stability as well as the desired bioavailability on drug release.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
3.
5-HYDROXY-1,4-NAPHTHALENEDIONE FOR USE IN THE TREATMENT OF CANCER
The present invention discloses compounds for inhibition of uncontrolled cell proliferation particularly cancer stem cells. Particularly, the invention relates to compounds of Formula (I) to (IV) for the treatment of cancer.
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 265/30 - 1,4-OxazinesHydrogenated 1,4-oxazines not condensed with other rings
C07C 235/10 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
C07C 217/24 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system containing rings other than six-membered aromatic rings
The invention relates to use of a compound of Formula I for inhibition of V-ATPase activity in a cell and a method of treating viral infections using the compounds of Formula I.
The invention relates to use of a compound of Formula I for inhibition of V-ATPase activity in a cell and a method of treating viral infections using the compounds of Formula I.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
The present invention relates to pharmaceutical compositions comprising compound of Formula IV, along with a solubilizing agent and a process to prepare the same. The said pharmaceutical compositions have enormous applications in cancer therapy. The present invention has come up with a novel and innovative pharmaceutical composition for the compounds of Formula IV that show significant stability as well as the desired bioavailability on drug release.
A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
The present invention relates to pharmaceutical compositions comprising compound of Formula IV, along with a solubilizing agent and a process to prepare the same. The said pharmaceutical compositions have enormous applications in cancer therapy. The present invention has come up with a novel and innovative pharmaceutical composition for the compounds of Formula IV that show significant stability as well as the desired bioavailability on drug release.
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
The present invention discloses compounds for inhibition of uncontrolled cell proliferation particularly in cancer stem cells. Particularly, the invention relates to compounds of Formula III to XIV for the treatment of cancer, such as breast and prostate cancer.
C07D 311/48 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 with one hydrogen atom in position 3 unsubstituted in the carbocyclic ring with two such benzopyran radicals linked together by a carbon chain
C07D 317/50 - Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 407/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
C07C 1/00 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
C07D 317/56 - Radicals substituted by sulfur atoms
8.
5-HYDROXY-1,4-NAPHTHALENEDIONE FOR USE IN THE TREATMENT OF CANCER
The present invention discloses compounds for inhibition of uncontrolled cell proliferation particularly cancer stem cells. Particularly, the invention relates to compounds of Formula (I) to (IV) for the treatment of cancer.
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention discloses compounds for inhibition of uncontrolled cell proliferation particularly cancer stem cells. Particularly, the invention relates to compounds of Formula I to XXII for the treatment of cancer.
C07D 407/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 295/088 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
The invention relates to use of a compound of Formula I for inhibition of V-ATPase activity in a cell and a method of treating viral infections using the compounds of Formula I.
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention discloses compounds for inhibition of uncontrolled cell proliferation particularly cancer stem cells. Particularly, the invention relates to compounds of Formula I to XXII for the treatment of cancer.
A61K 31/00 - Medicinal preparations containing organic active ingredients
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention discloses compounds for inhibition of uncontrolled cell proliferation particularly in cancer stem cells. Particularly, the invention relates to compounds of Formula III to XIV for the treatment of cancer, such as breast and prostate cancer.
C07D 311/48 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 with one hydrogen atom in position 3 unsubstituted in the carbocyclic ring with two such benzopyran radicals linked together by a carbon chain
C07D 317/50 - Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 407/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
C07C 1/00 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
C07D 317/56 - Radicals substituted by sulfur atoms
13.
Process for producing cellulose with low impurities from sugarcane bagasse
The present invention relates to a process for producing cellulose with low inorganic impurities from sugarcane bagasse, the process comprising treating prehydrolysed sugarcane bagasse with a mixture of sulfite and at least one alkali to obtain residue having undissolved cellulose along with lignin rich liquor. The residue having undissolved cellulose is further subjected to delignification and addition of at least one enzyme to obtain a cellulose rich pulp. The cellulose rich pulp obtained is then treated with bleaching agents followed by separating pure cellulose rich pulp having high a-cellulose content and low inorganic impurities.
The present invention discloses compounds for inhibition of uncontrolled cell proliferation particularly in cancer stem cells. Particularly, the invention relates to compounds of Formula III to XIV for the treatment of cancer, such as breast and prostate cancer.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
C07H 17/04 - Heterocyclic radicals containing only oxygen as ring hetero atoms
A biofiller for rubber reinforcement; said biofiller is surface treated up to 10% by weight of microcrystalline lignocellulose with aldehyde and/or ketone. The said biofiller has economic significance as well as reduces pollution as it replaces 2% carbon black from the rubber composition which is substantial amount after reviewing overall use of carbon black in rubber industries such as tyre industry, worldwide. A rubber composition comprising the said biofiller and its various applications such as tyre, shoes, bags, belts, etc.
The present invention discloses a process for preparing high flash point frothing agent by treating an aldehyde with an alcohol in the presence of an acid catalyst at elevated temperature and further adding a carbonate salt to obtain the frothing agent and polymer.
The present invention relates to a process for producing cellulose with low inorganic impurities from sugarcane bagasse, the process comprising treating prehydrolysed sugarcane bagasse with a mixture of sulfite and at least one alkali to obtain residue having undissolved cellulose along with lignin rich liquor. The residue having undissolved cellulose is further subjected to delignification and addition of at least one enzyme to obtain a cellulose rich pulp. The cellulose rich pulp obtained is then treated with bleaching agents followed by separating pure cellulose rich pulp having high α-cellulose content and low inorganic impurities.
A biofiller for rubber reinforcement; said biofiller is surface treated upto 10 % by weight of microcrystalline lignocellulose with aldehyde and / or ketone. The said bio-filler has economic significance as well as reduces pollution as it replaces 2 % carbon black from the rubber composition which is substantial amount after reviewing overall use of carbon black in rubber industries such as tyre industry, worldwide. A rubber composition comprising the said biofiller and its various applications such as tyre, shoes, bags, belts, etc.
The present invention relates to a process for preparing unsaturated ketone by using an ion exchange polymer as a catalyst. The process comprises the steps of mixing an aldehyde with a ketone and passing the mixture of aldehyde and ketone through a fixed bed catalytic reactor comprising the ion exchange polymer at a temperature of at least 60 degree C. at atmospheric pressure for a retention period of 30-50 min. The unsaturated ketone obtained from the reaction is purified by distillation and 99.5% pure unsaturated ketone with a yield of not less than 80% is obtained.
C07C 45/74 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by reactions not involving the formation of C=O groups by isomerisationPreparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by reactions not involving the formation of C=O groups by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing C=O groups with the same or other compounds containing C=O groups combined with dehydration
C07C 45/82 - SeparationPurificationStabilisationUse of additives by change in the physical state, e.g. crystallisation by distillation
20.
A PROCESS FOR PREPARATION OF HIGH FLASH POINT FROTHING AGENT
The present invention discloses a process for preparing high flash point frothing agent by treating an aldehyde with an alcohol in the presence of an acid catalyst at elevated temperature and further adding a carbonate salt to obtain the frothing agent and polymer.
The present invention discloses a process for preparing high flash point frothing agent by treating an aldehyde with an alcohol in the presence of an acid catalyst at elevated temperature and further adding a carbonate salt to obtain the frothing agent and polymer.
The present invention provides compounds of formula (I), compositions, uses thereof and methods for eradicating or inhibiting proliferation of cancer stem cells which includes killing; and/or inducing apoptosis in cancer stem cells. Included within the scope of such compounds, compositions, uses thereof and methods are those in which proliferation of cancer stem cells are selectively eradicated or inhibited.
The present invention provides compounds of formula (I), compositions, uses thereof and methods for inhibiting proliferation or obliterating cancer stem cells which includes killing; and/or inducing apoptosis in cancer stem cells. Included within the scope of such compounds, compositions, uses thereof and methods are those in which proliferation of cancer stem cells are selectively eradicated or inhibited.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 243/38 - [b, e]- or [b, f]-condensed with six-membered rings
24.
COMPOUNDS FOR INHIBITION OF UNREGULATED CELL GROWTH
Compounds For Inhibition Of Unregulated Cell Growth The present invention relates to compounds of Formula I for inhibition or eradication of unregulated cell growth.
The present invention relates to a process for preparing unsaturated ketone by using an ion exchange polymer as a catalyst. The process comprises the steps of mixing an aldehyde with a ketone and passing the mixture of aldehyde and ketone through a fixed bed catalytic reactor comprising the ion exchange polymer at a temperature of atleast 60 degree C at atmospheric pressure for a retention period of 30-50 min. The unsaturated ketone obtained from the reaction is purified by distillation and 99.5 % pure unsaturated ketone with a yield of not less than 80% is obtained.
C07C 45/74 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by reactions not involving the formation of C=O groups by isomerisationPreparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by reactions not involving the formation of C=O groups by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing C=O groups with the same or other compounds containing C=O groups combined with dehydration
C07C 49/203 - Unsaturated compounds containing keto groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
The present invention provides agents useful for eliminating tumour initiating cells, compositions thereof, uses thereof and methods of using the same.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
27.
Synthesis of cleistanthin A and derivatives thereof
The present invention provides a method for preparing Cleistanthin A, a diphyllin glycoside, derivatives thereof and intermediates thereto. In particular the present invention provides in one of the aspect a method for synthesis of compound of formula D a key intermediate of diphyllin, which can be carried out in a shorter duration and at an ordinary temperature.
C07D 407/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 317/54 - Radicals substituted by oxygen atoms
C07D 407/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
28.
SYNTHESIS OF CLEISTANTHIN A AND DERIVATIVES THEREOF
The present invention provides a method for preparing Cleistanthin A, a diphyllin glycoside, derivatives thereof and intermediates thereto. In particular the present invention provides in one of the aspect a method for synthesis of compound of formula D a key intermediate of diphyllin, which can be carried out in a shorter duration and at an ordinary temperature.
The present invention provides a method for preparing Cleistanthin A, a diphyllin glycoside, derivatives thereof and intermediates thereto. In particular the present invention provides in one of the aspect a method for synthesis of compound of formula D a key intermediate of diphyllin, which can be carried out in a shorter duration and at an ordinary temperature.
The present invention provides a culture medium for selectively enriching and maintaining stem cells or cancer stem-like cells comprising basic nutrients, gelatin, methyl cellulose and optionally growth factors or other supplementary elements in an effective amount wherein the culture medium is essentially serum free. The present invention further provides feeding medium comprising components similar to the culture medium except the feeding medium is devoid of methyl cellulose. Present invention still further provides cell cultures comprising stem cells or cancer stem-like cells and the culture medium of the present invention. Also provides are methods for selectively enriching and maintaining stem cells or cancer stem-like cells using the culture medium of the present invention and kits for the same.
The present invention provides compounds having the general formula I or pharmaceutically acceptable salt thereof, and pharmaceutically acceptable compositions having ability to inhibit proliferation of and/or eradicate cancer cells and/or cancer cells having significant self-renewal potential, such as cancer stem cells (CSCs). Such compounds have the general formula I. The invention also provides the use of a compound of formula I, or a pharmaceutically acceptable salt thereof, or pharmaceutically acceptable compositions thereof in inhibiting the proliferation of and/or eradicating cancer cells and/or cancer cells having significant self-renewal potential, such as cancer stem cells (CSCs).
A01N 43/16 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom six-membered rings with oxygen as the ring hetero atom
A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
32.
MOLECULES WITH ANTICANCER ACTIVITY AND USES THEREOF
The present invention relates to molecules represented by compounds having the general formula I or pharmaceutically acceptable salt thereof, and pharmaceutically acceptable compositions for inhibiting proliferation of and/or eradication of cancer cells and/or cancer cells having significant self-renewal potential, such as cancer stem cells (CSCs). Such compounds have the general formula (I): The invention also provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, or pharmaceutically acceptable compositions thereof for inhibiton the proliferation of and/or eradication of cancer cells and/or cancer cells having significant self-renewal potential, such as cancer stem cells (CSCs) for remission of cancer.
A01N 43/26 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with two or more hetero atoms five-membered rings
A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
The present invention relates to an alpha-cellulose with high molecular weight and purity and a process for obtaining the same from lignocellulosic material. The lignocellulosic raw material is treated by contacting it with high pressure steam at temperature in the range 190°C - 200°C for at least 2 minutes to solubilize the hemicellulose fraction. The undissolved fibrous organic biomass is washed with hot soft water to give the pretreated lignocellulosic material. The pretreated lignocellulosic material is pulped using sulfite, alkali and anthraquinone at a temperature of at least 120 °C and holding time of at least 15 minutes for solubilizing lignin component by converting into lingnosulfonte. The washed and screened pulp is bleached, washed to obtain the pulp containing at least 92% alpha - cellulose having high molecular weight in the range of 10,00,000-25,00,000. Such alpha-cellulose with high molecular weight and purity is suitable for converting into biodegradable derivatives.
The present invention is directed towards providing oligonucleotide primer sequences for the detection of Leptospira species in biological and environmental samples. The oligonucleotide primer sequences of the present invention are capable of detecting DNA of Leptospira species in a given sample using molecular protocol for example a polymerase chain reaction (PCR) technique. The present invention also provides a method and a kit for detecting leptospiral DNA in a given sample with high specificity.
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
35.
A METHOD OF OBTAINING POLICOSANOLS FROM NATURAL MATERIAL
The present invention relates to a method of obtaining policosanols from natural materials. More particularly it relates to a method of obtaining policosanols by reacting wax or waxy material obtained from natural source with hydrogen in presence of catalyst. The present invention also provides policosanols in unrefined and refined form obtained by the present invention method.
The present invention relates to a Saccharomyces cerevisiae MTCC 5452 strain capable of fermenting C-5 sugar which is not genetically modified strain. The present invention also provides a fermentative method for producing ethanol with the said strain, comprising incubating culture of Saccharomyces cerevisiae MTCC 5452 with a fermentation medium comprising at least C-5 sugar carbon source under favourable pH and at temperature and fermentation conditions for a sufficient period to obtain ethanol with higher productivity.
The present invention provides a mutagenized strain of Bacillus coagulans, MTCC 5454, and discloses its use in the production of Lactic acid. The invention also provides an efficient, rapid method for increased production of lactic by using the strain MTCC 5454. The present invention uses inexpensive natural sugars as carbon source for conversion to lactic acid.
There is provided a new strain, that is Aspergillus fumigatus, MTCC 5453, and its use in the production of fructo-oligosaccharide. The invention also provides an efficient, rapid and method for increased production of fructo-oligosaccharide by using the strain Aspergillus fumigatus MTCC 5453.
The present invention relates to a process for preparing compound of formula (I) that is Cleistanthin A. The process comprises the steps of reacting compound of formula (II) with compound of formula (III) in the presence of a first solvent, quarternary ammonium salt and first alkali to form compound of formula (IV). The compound of formula (IV) is further treated with a second solvent and a second alkali to form compound of formula (I). The present invention also relates to the preparation of salt of compound of formula (IV) that is Cleistanthin A acetate.
C07D 407/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The present invention relates to a process for preparing compound of formula (I) that is Cleistanthin A. The process comprises the steps of reacting compound of formula (II) with compound of formula (III) in the presence of a first solvent, quarternary ammonium salt and first alkali to form compound of formula (IV). The compound of formula (IV) is further treated with a second solvent and a second alkali to form compound of formula (I). The present invention also relates to the preparation of salt of compound of formula (IV) that is Cleistanthin A acetate.
patents
